Paving the Road for Chimeric Antigen Receptor T Cells - American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification

Sep 29, 2026

Consensus manuscript addressing challenges and practical solutions to improve the efficiency of clinical center certification for chimeric antigen receptor T (CAR-T) cell therapy. Published as a Transplantation and Cellular Therapy task force statement within Transplant Cell Therapy, it outlines policy, implementation considerations, and operational approaches aimed at standardizing certification processes across centers. The article also includes open-access licensing information and full disclosures of authors’ contributions and financial relationships with pharmaceutical and related entities.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages25

Reading Time1 h 3 min

AccessFree to download

Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript | | HHS Public Access
Author manuscript
Transplant Cell Ther. Author manuscript; available in PMC 2026 January 06. | | --- | --- | Published in final edited form as: Transplant Cell Ther. 2023 April ; 29(4): 228–239. doi:10.1016/j.jtct.2023.01.021 . Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)) *Correspondence and reprint requests: Frederick L. Locke, Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, 12902 Magnolia Dr, FOB-3, Tampa, FL 33612 [sarah_nikiforow@dfci.harvard.edu](sarah_nikiforow@dfci.harvard.edu) (S. Nikiforow), [frederick.locke@moffitt.org](frederick.locke@moffitt.org)[ ](frederick.locke@moffitt.org)(F.L. Locke) . Authorship statement: B.L. collected the data, contributed data or analysis tools, performed the analysis, and wrote the paper. F.L.L. conceived of the project, assembled the authors, and wrote all drafts ofthe manuscript. H.H. contributed to writing and reviewing the manuscript. J.A. contributed to writing and reviewing the manuscript. K.H. contributed to writing and reviewing the manuscript. K.K. contributed to establishing the 80/20 Task Force and to writing and reviewing the manuscript. M.J. contributed to writing and reviewing the manuscript. M.P. contributed to writing and reviewing the manuscript. M.F. contributed to writing and reviewing the manuscript. M.G. contributed to writing and reviewing the manuscript. M-A.P. contributed to establishing the 80/20 Task Force and to writing and reviewing the manuscript. N.F. contributed to writing and reviewing the manuscript. P.K. contributed to writing and reviewing the manuscript. P.W. contributed to writing and reviewing the manuscript. R.G. contributed to writing and reviewing the manuscript. S.N. conceived of the project, assembled the authors, and wrote all drafts ofthe manuscript. T.H. contributed to writing and reviewing the manuscript. S.N. and F.L.L. contributed equally to this work. Conflict of interest statement: The authors disclose some relationships with the pharmaceutical industry, including serving as advisors, consultants, and employees. B.L. reports compensation for serving on the scientific advisory boards of Akron Bio, Avectas, Immuneel Therapeutics, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, UTC Therapeutics, and Vycellix; compensation for consulting for GSK; and compensation and equity from Capstan Therapeutics as a cofounder and member of the scientific advisory board. As co-founder of Tmunity Therapeutics, he received equity. Conflict of interest is managed in accordance with University of Pennsylvania policy and oversight. F.L.L. has received honoraria for serving as a scientific advisor to Allogene, Amgen, bluebird bio, BMS/Celgene, Calibr, Cellular Biomedicine Group, GammaDelta Therapeutics, Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen, and Umoja. As an investigator, he has received institutional support from Kite Pharma, Allogene, Novartis, and bluebird bio. He has received consulting fees from Cowen, EcoR1, Emerging Therapy Solutions, and Gerson Lehrman Group. He also has received honoraria for education from Aptitude Health, ASH, BioPharma Communications, CARE Education, Clinical Care Options Oncology, Imedex, and the Society of Immunotherapy of Cancer. H.H. is a co-founder of both AlloVir and Marker Therapeutics and has received equity, and also serves on the advisory board of Marker Therapeutics. She has received fees for serving as a consultant for Tessa Therapeutics, GSK, Gilead, Kiadis, Takeda, and Mesoblast. Also for consulting,

FAQs

What is the document focused on regarding CAR-T therapy?

It provides a task force consensus addressing how to improve the efficiency of clinical center certification related to chimeric antigen receptor T cell therapies.

Which organization is associated with the 80/20 task force consensus?

The consensus is linked to the American Society for Transplantation and Cellular Therapy (ASTCT) 80/20 Task Force.

What information about authorship and disclosures is included?

The document includes an authorship statement describing individual contributions and a conflict-of-interest statement detailing financial relationships with industry.

Sep 29, 2026

Upload by Mary Man